{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Improved in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Stable in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Worsened in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Improved in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Stable in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Worsened in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Improved in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Stable in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Worsened in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Improved in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Stable in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Worsened in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Improved in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Stable in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Worsened in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Improved in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Stable in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Worsened in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Improved in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Stable in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Worsened in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Improved in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"Stable in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"worsened in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Improved in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Stable in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Worsened in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Improved in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Stable in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Worsened in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Improved in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Stable in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Worsened in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Improved in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Stable in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Worsened in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Improved in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Stable in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Worsened in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Improved in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Stable in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Worsened in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Improved in financial difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Stable in financial difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Worsened in financial difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","groups":[{"description":"This reporting group includes all Phase 1 participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","id":"OG000","title":"Phase 1 PRO Evaluable Population"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"From start of study treatment until end of treatment (maximum of 8 years approximately)","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)","type":"SECONDARY","unitOfMeasure":"Participants"}